Monday broker round-up
19th Sep 2016 09:52
(ShareCast News) - Lloyds: Jefferies reiterates buy with a target price of 67p. Astrazeneca: UBS reiterates buy, 5480p target. Britvic: JP Morgan keeps at underweight with a 590p target. Unilever: UBS reiterates neutral with a 3380p target. IHG: HSBC starts coverage at reduce with a 2900p target.
Read moreBroker tips: Pets at Home, Wood Group, Astrazeneca
12th Sep 2016 11:03
(ShareCast News) - Citigroup initiated coverage of Pets at Home at 'buy' with a 275p price target, given its expectation of the medium-term margin upside opportunity and cash returns. The bank reckons that over the next 10 years, the vet business could generate an incremental £40m earnings before in
Read moreMonday broker round-up
12th Sep 2016 09:24
(ShareCast News) - Autotrader: Barclays reiterates equal-weight with a target price of 375p. Hikma: Jefferies maintains buy with a 2500p target. Wood Group: Exane BNP Paribas upgrades to buy with a 815p target. Man Group: Citigroup upgrades to buy with a 137p target. McCarthy & Stone: Goldman Sac
Read moreJefferies upgrades AstraZeneca to 'buy'
12th Sep 2016 07:34
(ShareCast News) - Jefferies upgraded AstraZeneca to 'buy' from 'hold' and lifted the price target to 5,800p from 5,400p saying it sees a much higher probability of success and larger market opportunity from the MYSTIC study than consensus implies. The MYSTIC study is a global, phase 3 study of the
Read moreConsort Medical signs agreement with AstraZeneca
7th Sep 2016 08:43
(ShareCast News) - Consort medical, a provider of advanced technology for drugs, has signed a new contract with pharmaceutical giant AstraZeneca for the supply of its Bespak respiratory devices. AstraZeneca and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Be
Read moreSector movers: Vodafone weighs on mobile telecoms
1st Sep 2016 21:10
(ShareCast News) - News that CK Hutchison Holdings and VimpelCom had won European Union approval to merge, in the process creating Italy´s biggest wireless telecommunications provider, sent stock in Vodafone sharply lower and its sector gauge with it. Vodafone´s own unit in that Mediterranean countr
Read moreAstraZeneca offloads anaesthetic rights to Aspen
1st Sep 2016 07:41
(ShareCast News) - AstraZeneca announced on Thursday morning that it has completed its commercialisation agreement with Aspen Global Incorporated, for rights to its global anaesthetics portfolio outside the US. The FTSE 100 pharmaceutical firm said the agreement covers seven established medicines -
Read moreThursday newspaper share tips: WPP and Astrazeneca
25th Aug 2016 14:47
(ShareCast News) - The mood in advertising giant WPP should be pretty good, opines Financial Times' Lex column, which, in something of a novelty, cites Martin Sorrell's healthy tan. Something to do with enhanced moods due to the sun and serotonin release, the column wheezed. It noted that, as was t
Read moreShire, AstraZeneca and Hikma hit by Hillary Clinton's pharma-bashing
25th Aug 2016 09:14
(ShareCast News) - Hikma Pharmaceuticals, Shire and AstraZeneca were among FTSE-listed drug companies slipping lower on Thursday morning, following comments from US presidential favourite Hillary Clinton on pharmaceutical pricing that hit peers across the Atlantic overnight. Clinton joined senators
Read moreAstraZeneca sells antibiotics business to Pfizer for £1.2bn
24th Aug 2016 07:11
(ShareCast News) - AstraZeneca has agreed to sell its antibiotics business to US giant Pfizer for staged payments amounting to $1.6bn (£1.2bn) plus recurring, double-digit royalties on future sales. The FTSE 100 group said the sale would reinforces its focus on developing medicines in its three main
Read moreFTSE 100 movers: Housebuilders lead equities higher
23rd Aug 2016 13:58
(ShareCast News) - The FTSE 100 rose 0.66% to 6,873.69 points in afternoon trade on Tuesday, with housebuilders topping the London index. Persimmon led housebuilders higher after reporting a better-than-expected jump in first half profits. Pre-tax profit rose 29% to £352.3m in the six months to 30 J
Read moreAstraZeneca completes licensing agreement with LEO Pharma
16th Aug 2016 07:07
(ShareCast News) - AstraZeneca has completed a licensing agreement with LEO Pharma, a specialist in dermatology care, for the global licence to monoclonal antibody tralokinumab in skin diseases. Upon completion of the agreement, LEO Pharma made a payment to AstraZeneca of $115m for the exclusive, gl
Read moreThursday broker round-up
11th Aug 2016 19:13
(ShareCast News) - Astrazeneca: Berenberg reiterates buy with a target price of 5600p. Legal & General: RBC maintains outperform with a 300p target. Lloyds: JP Morgan reiterates neutral with a 62p target. Centamin: RBC stays at speculative risk with a 190p target. Staffline: Berenberg reiterates
Read moreAstrazeneca ups interest in Moderna Therapeutics with $140m investment
10th Aug 2016 15:17
(ShareCast News) - Astrazeneca has upped its equity interest in Moderna Therapeutics with a $140m investment as part of the biotechnology company's preferred-stock financing. Astrazeneca had already purchased a stake in Massachusetts-based Moderna to develop messenger RNA medicines for the potential
Read moreTuesday broker round-up
9th Aug 2016 12:42
(ShareCast News) - Aviva: Goldman Sachs reiterates buy with a target price of 480p. Antofagasta: RBC maintains sector perform with a 500p target. Informa: Numis reiterates buy with a 845p target. Astrazeneca: JP Morgan stays at neutral with a 4900p target. Topps Tiles: Berenberg reiterates hold w
Read more